The aim of our study is to evaluate the uptake behavior of [64Cu]-DOTAGA-PSMA with DOTAGA as a possible stable chelator compared to [18F]-PSMA PET–CT in a routine clinical setting in PCa patients. The gene discussed is FOLH1; the disease is posterior cortical atrophy.